Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization

Authors

Mark W. Majewski, Marquette University
Disha M. Gandhi, Marquette UniversityFollow
Ricardo Rosas Jr., Marquette University
Revathi Kodall, University of Wisconsin - Milwaukee
Leggy A. Arnold, University of Wisconsin - Milwaukee
Chris Dockendorff, Marquette UniversityFollow

Document Type

Article

Language

eng

Publication Date

2019

Publisher

American Chemical Society

Source Publication

ACS Medicinal Chemistry Letters

Source ISSN

1948-5875

Abstract

A novel class of bivalent ligands targeting putative protease-activated receptor (PAR) heteromers has been prepared based upon reported antagonists for the subtypes PAR1 and PAR2. Modified versions of the PAR1 antagonist RWJ-58259 containing alkyne adapters were connected via cycloaddition reactions to azide-capped polyethylene glycol (PEG) spacers attached to imidazopyridazine-based PAR2 antagonists. Initial studies of the PAR1–PAR2 antagonists indicated that they inhibited G alpha q-mediated calcium mobilization in endothelial and cancer cells driven by both PAR1 and PAR2 agonists. Compounds of this novel class hold promise for the prevention of restenosis, cancer cell metastasis, and other proliferative disorders.

Comments

Accepted version. ACS Medicinal Chemistry Letters, Vol. 10, No. 1 (2019): 121-126. DOI. © 2019 American Chemical Society. Used with permission.

Recommended Citation

Majewski, Mark W.; Gandhi, Disha M.; Rosas, Ricardo Jr.; Kodall, Revathi; Arnold, Leggy A.; and Dockendorff, Chris, "Design and Evaluation of Heterobivalent PAR1–PAR2 Ligands as Antagonists of Calcium Mobilization" (2019). Chemistry Faculty Research and Publications. 966.
https://epublications.marquette.edu/chem_fac/966